D609 Suppresses Antituberculosis Response by Regulating Dendritic Cells Antigen Presentation

Honglin Liu1,2, Huimin Huang1, Zhen Huang1

  • 1Department of Clinical Laboratory, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.

PubMed

Insights

Inhibiting phosphatidylcholine-specific phospholipase C (PC-PLC) impairs dendritic cell (DC) function, hindering the immune response against tuberculosis (TB) by reducing T cell activation and bacterial clearance.

Area of Science:

  • Immunology
  • Microbiology

Background:

  • Dendritic cells (DCs) are crucial for initiating adaptive immune responses.
  • The role of phosphatidylcholine-specific phospholipase C (PC-PLC) in DC-mediated immunity against Mycobacterium tuberculosis (M.tb) remains unclear.

Purpose of the Study:

  • To investigate the function of PC-PLC in dendritic cells (DCs) during the immune response to tuberculosis (TB).
  • To determine the impact of PC-PLC inhibition on DC-mediated antigen presentation and T cell activation.

Main Methods:

  • Mice infected with M.tb were pretreated with a PC-PLC inhibitor (D609).
  • Bacterial loads, inflammatory markers, and DC subsets (cDC1, cDC2) were assessed in vivo.
  • In vitro, bone marrow-derived dendritic cells (BMDCs) were treated with D609 to evaluate cytokine production, antigen processing, and T cell activation capacity.

Main Results:

  • PC-PLC inhibition increased M.tb bacterial load and inflammation in mice.
  • D609 treatment reduced the number of DCs, particularly cDC1 and cDC2 subsets.
  • In vitro, D609-treated BMDCs showed impaired cytokine production, antigen processing, and T cell activation.

Conclusions:

  • PC-PLC is essential for DC function, including cytokine production, migration, and antigen presentation.
  • Inhibition of PC-PLC compromises the anti-TB immune response by impairing DC-T cell interactions.
  • Targeting PC-PLC in DCs may offer novel therapeutic strategies for tuberculosis treatment.
Abstract